{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:51Z","timestamp":1791478071566,"version":"4.3.4"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Epstein-Barr virus (EBV) is a ubiquitous human gamma-herpesvirus causally linked to a diverse spectrum of lymphoid malignancies. This review provides a comprehensive overview of EBV-associated lymphomas, encompassing their global epidemiology, the intricate pathogenesis driven by viral latency proteins and complex host immune interactions, and the varied clinical presentations of distinct subtypes. We delve into the detailed pathological features, molecular characteristics, and diagnostic strategies for classic Hodgkin lymphoma (cHL), Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), post-transplant lymphoproliferative disorder (PTLD), and extra-nodal NK\/T-cell lymphoma, nasal type (ENKTL). Current subtype-specific treatment paradigms are critically evaluated, along with a thorough exploration of emerging therapeutic avenues, including novel immunotherapeutic approaches such as immune checkpoint inhibitors, adoptive cell therapies like EBV-specific cytotoxic T lymphocytes and chimeric antigen receptor T-cells (CAR-T), and targeted molecular therapies. Finally, we highlight the persistent challenges, critical knowledge gaps, and promising future prospects, including preventative and therapeutic vaccine strategies, aimed at optimizing diagnostic precision and improving long-term outcomes for patients afflicted with these heterogeneous and often aggressive diseases.<\/jats:p>","DOI":"10.3389\/fonc.2025.1677060","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T05:14:43Z","timestamp":1763961283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Epstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology"],"prefix":"10.3389","volume":"15","author":[{"given":"Soumyadeep","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumyaranjan","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1452","article-title":"Epstein\u2013Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt's lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein\u2013Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein\u2013Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","article-title":"Epstein\u2013Barr virus and its replication","volume-title":"Fields virology","author":"Kieff","year":"2007"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrc2846","article-title":"Epstein-Barr virus: a human carcinogen","volume":"10","author":"Young","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007370.","article-title":"EBV-encoded BART microRNAs target multiple pro-apoptotic pathways in epithelial cells","volume":"14","author":"Kung","year":"2018","journal-title":"PloS Pathog"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.6.1700","article-title":"Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1","volume":"17","author":"Kilger","year":"1998","journal-title":"EMBO J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1187","article-title":"Expression of LMP2A in EBV-associated lymphoproliferative disorders","volume":"98","author":"Latza","year":"2001","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/jb.91.3.1248-1256.1966","article-title":"Immunofluorescence in cells derived from Burkitt's lymphoma","volume":"91","author":"Henle","year":"1966","journal-title":"J Bacteriol"},{"key":"B11","article-title":"The Epstein-Barr virus microRNA BHRF1\u20131 targets the pro-apoptotic protein BCL2","volume":"90","author":"Strong","year":"2016","journal-title":"J Virol"},{"key":"B12","article-title":"Epstein-Barr virus biology and disease","volume-title":"Principles and Practice of Pediatric Oncology","author":"Cohen","year":"2016"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.20.13268-13279.2005","article-title":"Epstein-Barr virus latent membrane protein 2A (LMP2A) regulates B-cell survival by modulating the expression of the prosurvival protein Bcl-xL","volume":"79","author":"Mancao","year":"2005","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0450","article-title":"Circulating Epstein-Barr virus DNA as a tumor marker for nasopharyngeal carcinoma","volume":"10","author":"Lo","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B15","article-title":"Epstein-Barr virus-encoded LMP1: a paradigm for oncogene-mediated evasion of apoptosis","volume":"95","author":"Dawson","year":"2006","journal-title":"Adv Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14959-14973.2005","article-title":"Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB and IRF7 leads to induction of a large number of interferon-stimulated genes","volume":"79","author":"Mainou","year":"2005","journal-title":"J Virol"},{"key":"B17","article-title":"Epstein-Barr virus latency: LMP2, a regulatory protein","volume":"303","author":"Longnecker","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"B18","article-title":"Immune evasion by Epstein-Barr virus","volume":"391","author":"Ressing","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B19","article-title":"Antiviral activity of interferons","volume":"170","author":"Moore","year":"2003","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.10.001","article-title":"Integrative analysis reveals selective 9p24.1 amplification and increased PD-1 ligand expression in EBV+ lymphomas","volume":"20","author":"Green","year":"2010","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-718121","article-title":"PD-1 blockade in Hodgkin lymphoma","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25783","article-title":"Epstein-Barr virus-driven AID expression in gastric carcinoma","volume":"9","author":"Poudel-Neupane","year":"2018","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of Burkitt's lymphoma","volume":"18","author":"Hecht","year":"2000","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00817-07","article-title":"EBV latent genes, chromatin, and the host cell environment","volume":"81","author":"Kelly","year":"2007","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2346","article-title":"Tumor-associated macrophages promote the growth of EBV-positive nasopharyngeal carcinoma","volume":"72","author":"Komatsu","year":"2012","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/13.S1.23","article-title":"Viruses and Hodgkin's lymphoma","volume":"13","author":"Jarrett","year":"2002","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2141.2011.08572.x","article-title":"The aetiology of Hodgkin lymphoma","volume":"154","author":"Hjalgrim","year":"2011","journal-title":"Br J Haematol"},{"key":"B28","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk stratification, and treatment","volume":"98","author":"Ansell","year":"2023","journal-title":"Am J Hematol"},{"key":"B29","first-page":"594","article-title":"Endemic Burkitt lymphoma: a disease of children in sub-Saharan Africa","volume":"81","author":"Mbulaiteye","year":"2003","journal-title":"WHO Bull"},{"key":"B30","article-title":"Epstein-barr virus and kaposi's sarcoma herpesvirus\/human herpesvirus 8","volume-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","year":"1997"},{"key":"B31","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0869","article-title":"EBV-associated diffuse large B-cell lymphoma of the elderly","volume":"102","author":"Oyama","year":"2003","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000021","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"46","author":"Ok","year":"2014","journal-title":"Pathology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.127","article-title":"EBV-positive diffuse large B-cell lymphoma, NOS: a clinicopathologic study of 60 cases","volume":"29","author":"Liu","year":"2016","journal-title":"Mod Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13251","article-title":"Posttransplant lymphoproliferative disorder: pathogenesis, risk factors, and management","volume":"22","author":"Styczynski","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-794109","article-title":"International consensus recommendations on the management of post-transplant lymphoproliferative disorders","volume":"130","author":"Trappe","year":"2017","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.6.948","article-title":"Clinical characteristics and treatment outcomes of extranodal natural killer\/T-cell lymphoma, nasal type, in Korea: a retrospective analysis of 37 cases","volume":"20","author":"Lee","year":"2005","journal-title":"J Korean Med Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline\u2013based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"B41","article-title":"Burkitt lymphoma","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2017"},{"key":"B42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pathol.2019.10.017","article-title":"Epstein\u2013Barr virus (EBV)-associated lymphoid proliferations: diagnostic approach and practical application","volume":"52","author":"Chan","year":"2020","journal-title":"Pathology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04935.x","article-title":"Quantification of circulating EBV DNA in the diagnosis and monitoring of NK\/T-cell lymphomas","volume":"124","author":"Au","year":"2004","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp367","article-title":"Prognostic significance of plasma EBV DNA load in extranodal NK\/T-cell lymphoma, nasal type","volume":"20","author":"Lin","year":"2009","journal-title":"Ann Oncol"},{"key":"B45","unstructured":"NCCN Guidelines for Hodgkin Lymphoma\n          \n          \n          \n          2023"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01477","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma","volume":"40","author":"Kwong","year":"2022","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783682","article-title":"A randomized phase II study of DA-EPOCH-R versus standard chemotherapy for patients with newly diagnosed Burkitt lymphoma","volume":"130","author":"Jacobson","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04219-1","article-title":"A phase II study of ibrutinib in combination with R CHOP in Epstein-Barr virus-positive diffuse large B cell lymphoma (IVORY)","volume":"100","author":"Park","year":"2021","journal-title":"Ann Hematol"},{"key":"B49","first-page":"S258","article-title":"Nanatinostat with or without valganciclovir in patients with relapsed\/refractory EBV-positive PTCL (NAVAL-1 stage 1)","volume":"46","author":"Navarro","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B50","first-page":"S259","article-title":"Global phase II expansion study of nanatinostat + valganciclovir in EBV+ relapsed\/refractory peripheral T cell lymphomas (NAVAL 1 Stage 2)","volume":"46","author":"Chang","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017013","article-title":"Tabelecleucel for posttransplant lymphoproliferative disorder after hematopoietic stem cell or solid organ transplant: results of two multicenter phase 3 studies","volume":"140","author":"Prockop","year":"2022","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02534","article-title":"Avelumab for relapsed or refractory extranodal NK\/T-cell lymphoma: phase II study","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740918","article-title":"Nivolumab for EBV-positive lymphomas: early results from a phase 2 trial","volume":"129","author":"Khodadoust","year":"2017","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278353","article-title":"A phase II study of brentuximab vedotin in CD30-positive EBV-associated lymphomas","volume":"106","author":"Yoon","year":"2021","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008505","article-title":"EBV-specific cytotoxic T lymphocytes for relapsed extranodal NK\/T-cell lymphoma: phase II results","volume":"137","author":"Bollard","year":"2021","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcomes of EBV-specific T-cell therapy for posttransplant lymphoproliferative disease","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510436","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of autologous stem-cell transplantation","volume":"375","author":"Younes","year":"2016","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200420025","article-title":"Cytotoxic T lymphocyte therapy for Epstein\u2013Barr virus+ lymphomas","volume":"114","author":"Bollard","year":"2004","journal-title":"J Clin Invest"},{"key":"B60","article-title":"EBV-specific cytotoxic T lymphocyte therapy for posttransplant lymphoproliferative disease","volume":"14","author":"Prockop","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00945-2","article-title":"CD30-directed CAR-T cells for relapsed Hodgkin lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019031063","article-title":"CD30-directed CAR T cells: a novel approach for Hodgkin lymphoma","volume":"3","author":"Pincus","year":"2019","journal-title":"Blood Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1072-6","article-title":"Inhibition of NF-\u03baB enhances the effect of bortezomib in Epstein-Barr virus-positive nasopharyngeal carcinoma cells","volume":"138","author":"Cai","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fgene.2020.00480","article-title":"The epigenetics of Epstein-Barr virus-associated lymphomas","volume":"11","author":"Jardin","year":"2020","journal-title":"Front Genet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3872","article-title":"EZH2 inhibition downregulates Epstein-Barr virus lytic gene expression and reactivates virus in EBV-positive gastric carcinoma","volume":"6","author":"Qi","year":"2015","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0372","article-title":"The proteasome inhibitor bortezomib sensitizes Epstein-Barr virus-associated tumor cells to chemotherapy","volume":"67","author":"Feng","year":"2007","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"677027","DOI":"10.3389\/fimmu.2021.677027","article-title":"Advances in EBV vaccine research: from animal models to human trials","volume":"12","author":"Kanekiyo","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"895312","DOI":"10.3389\/fimmu.2022.895312","article-title":"Virus-driven lymphoproliferative disorders in primary immunodeficiencies and immune dysregulation: from pathogenesis to treatment","volume":"13","author":"Bosch","year":"2022","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01103","article-title":"Inherited immunodeficiencies with high predisposition to Epstein\u2013Barr virus-driven lymphoproliferative diseases","volume":"9","author":"Latour","year":"2018","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2010-06-284935","article-title":"X-linked lymphoproliferative disease due to SAP\/SH2D1A deficiency: a multicenter study on the clinical and immunologic phenotype","volume":"117","author":"Booth","year":"2011","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated PI3K\u03b4 syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.06.014","article-title":"Novel mutations in MAGT1 cause X-linked immunodeficiency with EBV-associated lymphoproliferative disease (XMEN)","volume":"134","author":"Alkhairy","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B75","first-page":"935","article-title":"Human inborn errors of immunity: 2024 update of the IUIS Phenotypic Classification","volume":"44","author":"Tangye","year":"2024","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1677060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T05:14:48Z","timestamp":1763961288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1677060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":75,"alternative-id":["10.3389\/fonc.2025.1677060"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1677060","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"article-number":"1677060"}}